TP53 and B-cell chronic lymphocytic leukemia: An International Prognostic Index for CLL (CLL-IPI) incorporating five independent prognostic features (TP53 status, age, clinical stage, IGHV mutational status, and β2-microglobulin level) has recently been developed to allow more targeted CLL patient management in clinical practice and clinical trials [10].